SCHEDULE: Sabby Entities Disclose 9.9% Stake in Tempest Therapeutics

Sabby Management, Hal Mintz, and Sabby Volatility Warrant Master Fund report a 9.9% beneficial ownership stake in Tempest Therapeutics, Inc.

Summary

• Sabby Management, LLC, Hal Mintz, and Sabby Volatility Warrant Master Fund, Ltd. have jointly reported beneficial ownership of 492,223 shares of Tempest Therapeutics, Inc. Common Stock.
• This aggregate amount represents 9.9% of the class of securities.
• The reporting persons share both voting and dispositive power over all 492,223 shares.
• The filing was made under Rule 13d-1(b), indicating that the reporting persons are institutional investors and not seeking to change or influence control of the issuer, except for activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.9% beneficial ownership by an institutional investor group is generally a positive signal, indicating confidence in the company's value or future prospects. While it doesn't provide operational details, it suggests a notable investment interest.

Positives

• A significant institutional investor group, Sabby Management, Hal Mintz, and Sabby Volatility Warrant Master Fund, has taken a substantial 9.9% stake in Tempest Therapeutics, potentially signaling confidence in the company's future prospects.

Future Outlook

NA

Industry Context

The disclosure of a significant stake by an institutional investor group like Sabby Management in a biotechnology company such as Tempest Therapeutics can be viewed as a vote of confidence, potentially attracting further investor interest in the sector, especially for companies with promising pipelines or strategic positions.

Comparison to Industry Standards

• A 9.9% stake is a substantial position for an institutional investor, approaching the 10% threshold that often triggers additional reporting requirements or scrutiny. This level of ownership is common for active funds that seek to influence company strategy or governance, even if the filing states no intent to change control.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence stock price positively due to perceived validation of the company's value.
• Company Management: Awareness of a large institutional holder may influence strategic decisions and communication with the investment community.

Key Dates

Recommendation

The filing indicates a significant institutional investment, which is generally a positive signal. However, without additional operational or financial data from Tempest Therapeutics, a 'hold' recommendation is prudent. Investors should monitor future developments and the company's performance to assess the long-term implications of this ownership stake.

Keywords

Tempest Therapeutics, Sabby Management, Hal Mintz, Sabby Volatility Warrant Master Fund, Beneficial Ownership, SEC Filing, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals